Australia
Recent studies in early diagnostics underline just how much focus medical technology companies are making on developing different modalities for very early cancer diagnosis. Here are just some recent examples.
Axovant, one of Vivek Ramaswamy’s biotech companies best known for its catastrophic Alzheimer’s failure in September 2017, is replenishing its pipeline with a licensing deal with Australian company Benitec Biopharma.
The Australian biotech market, which was valued at nearly $23 billion last year, is expected to see some positive growth to $25.2 billion by 2025, according to a GlobalData analysis.
Mr Buccilli commenced with the Company in June 2014 as CFO and was appointed CEO in February 2015.
The group has bought 11 businesses in the past seven years.
The Annual Report is available on the Company’s website at www.gtglabs.com
Osprey Medical today released its Appendix 4C – Quarterly Cashflow Report for the period ending 30 September 2017.
PRESS RELEASES